Hologic Sells MammoTest To Siemens, Answering FTC Charge Of “Monopoly”
This article was originally published in The Gray Sheet
Executive Summary
Hologic will sell its MammoTest stereotactic breast biopsy system intellectual property to Siemens in response to Federal Trade Commission charges that the firm controls a "virtual monopoly" in the market